Organisation paid for research Program year 2025 Source: CMS Open Payments

Virginia Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$583,533

48 payments

Through program year 2025, Virginia Clinical Research is reported as receiving $583,533 in research payments, across 48 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $530 1
2023 Research $12,517 4
2022 Research $21,215 8
2021 Research $130,496 13
2020 Research $67,816 10
2019 Research $350,958 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $436,754 16 payments
  2. Janssen Research & Development, LLC $68,618 19 payments
  3. Mindera Corp $54,717 3 payments
  4. Biofrontera Inc. $10,926 3 payments
  5. Allergan Inc. $5,119 2 payments
  6. Celgene Corporation $4,218 3 payments
  7. Biofrontera Bioscience GmbH $3,180 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis $267,534 3 payments
  2. A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa Sunrise $84,861 4 payments
  3. A Phase 2b Multi Center Randomized Placebo and Active comparator controlled Double blind Study to Evaluate the Safety and Efficacy of Bermekimab JNJ77474462 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis $42,335 10 payments
  4. Pediatric Study in Children With Moderate to Severe Plaque Psoriasis $40,339 1 payment
  5. A Multicenter, Double-Blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-Term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa $29,859 2 payments
  6. Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis $14,446 6 payments
  7. A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis $11,837 3 payments
  8. A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz ) and BF-RhodoLED in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT). $10,396 2 payments
  9. A Multicenter Double Blind Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long Term Efficacy Safety and Tolerability Up to 2 Years in Subjects With Moderate to Severe Chronic Plaque Type Psoriasis Co $8,384 2 payments
  10. A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study to Determine the Efficacy and Safety of Oral Zpl389a 3 MG 10 MG 30 MG and 50 MG Capsules Administered for 16 Weeks in Subjects With Moderate to Severe Atopic Dermatitis $5,703 3 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $2,910 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record